#Calgary #Immuno-Oncology #Onco-ID #Syantra

Syantra Inc.: Pioneering New Frontiers in Cancer Treatment

Syantra, Inc., a cutting-edge biotechnology firm, has made a significant move in the field of cancer treatment with the establishment of a new therapeutic division. This division will focus on immuno-oncology drug discovery, making use of Syantra's innovative Onco-ID™ platform, which is currently pending patent approval. Emphasizing the need for advancements in cancer therapies, Syantra's efforts aim to reverse the corruption of immune cells linked to cancer, thereby enhancing the body's natural defense against tumors.

The Onco-ID™ platform represents a revolutionary approach that employs signals from the immune system to detect active cancer signatures within the body. According to Syantra's CEO, Rob Lozuk, the company has recognized that the same biological mechanisms utilized for cancer detection can also be employed to identify new drug targets and pave the way for novel treatments. This realization marks an exciting chapter in the company’s mission to combat cancer effectively.

“We've always recognized that the same biological mechanisms we use to detect early stage cancers could be adapted to identify new drug targets and create new paths to treatment,” says Lozuk.

Syantra's approach extends beyond merely discovering new therapies; it also includes improving patient selection and treatment monitoring, potentially leading to better outcomes for patients. The company aims to develop therapies that reprogram the tumor-immune interaction, allowing for a restoration of effective anti-cancer immunity.

Understanding Tumor Education

Syantra’s Principal Scientist, Olesya Kharenko, PhD, explains the concept of